Cover Image
市場調查報告書

小核醣核酸病毒感染的開發中產品分析

Infections Caused By Picornaviridae - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 251549
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
小核醣核酸病毒感染的開發中產品分析 Infections Caused By Picornaviridae - Pipeline Review, H2 2014
出版日期: 2014年09月10日 內容資訊: 英文 32 Pages
簡介

小核醣核酸病毒是小核醣核酸病毒屬,人體最常發現的感染性病毒的一種。主要症狀有咽喉炎及鼻水、鼻塞、噴嚏·咳嗽,再加上肌肉酸痛及疲勞、倦怠感、頭痛、肌肉無力、食欲不振等。主要治療藥有抗生素等。

本報告提供全球各國治療小核醣核酸病毒感染用的開發中產品開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

小核醣核酸病毒感染概要

治療藥的開發

  • 小核醣核酸病毒感染用開發中產品:概要
  • 小核醣核酸病毒感染用開發中產品:比較分析

各企業開發中的小核醣核酸病毒感染治療藥

大學/研究機關研究中的小核醣核酸病毒感染治療藥

開發中產品的概要

  • 初期階段的產品
  • 開發階段不明的產品

小核醣核酸病毒感染治療藥:開發中的產品一覽(各企業)

小核醣核酸病毒感染治療藥:研究中的產品一覽(大學/研究機關別)

小核醣核酸病毒感染治療藥的開發企業

  • Immunomedics, Inc.
  • Alios BioPharma, Inc.
  • AIMM Therapeutics B.V.
  • Indian Immunologicals Limited

小核醣核酸病毒感染:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 分子類別

藥物簡介

  • Picornavirus Nucleoside Analogs
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • Virus Protease Inhibitors
  • Interferon Lambda-1 Linked Fab Dimer
  • Monoclonal Antibodies for Parecho Virus Infections
  • Amiloride Derivatives
  • Picornaviral Vaccines

小核醣核酸病毒感染治療藥:暫停開發的產品

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5528IDB

Summary

Global Markets Direct's, 'Infections Caused By Picornaviridae - Pipeline Review, H2 2014', provides an overview of the Infections Caused By Picornaviridae's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Infections Caused By Picornaviridae, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Infections Caused By Picornaviridae and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Infections Caused By Picornaviridae
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Infections Caused By Picornaviridae and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Infections Caused By Picornaviridae products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Infections Caused By Picornaviridae pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Infections Caused By Picornaviridae
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Infections Caused By Picornaviridae pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Infections Caused By Picornaviridae Overview
  • Therapeutics Development
    • Pipeline Products for Infections Caused By Picornaviridae - Overview
    • Pipeline Products for Infections Caused By Picornaviridae - Comparative Analysis
  • Infections Caused By Picornaviridae - Therapeutics under Development by Companies
  • Infections Caused By Picornaviridae - Therapeutics under Investigation by Universities/Institutes
  • Infections Caused By Picornaviridae - Pipeline Products Glance
    • Early Stage Products
    • Unknown Stage Products
  • Infections Caused By Picornaviridae - Products under Development by Companies
  • Infections Caused By Picornaviridae - Products under Investigation by Universities/Institutes
  • Infections Caused By Picornaviridae - Companies Involved in Therapeutics Development
    • Immunomedics, Inc.
    • AIMM Therapeutics B.V.
    • Indian Immunologicals Limited
  • Infections Caused By Picornaviridae - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Molecule Type
  • Drug Profiles
    • Small Molecule to Inhibit Viral Protease for Viral Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Interferon Lambda-1 Linked Fab Dimer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Parecho Virus Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit RNA Polymerase for Viral Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • picornavirus vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Infections Caused By Picornaviridae - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Infections Caused By Picornaviridae, H2 2014
  • Number of Products under Development for Infections Caused By Picornaviridae - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Comparative Analysis by Unknown Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Infections Caused By Picornaviridae - Pipeline by Immunomedics, Inc., H2 2014
  • Infections Caused By Picornaviridae - Pipeline by AIMM Therapeutics B.V., H2 2014
  • Infections Caused By Picornaviridae - Pipeline by Indian Immunologicals Limited, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Infections Caused By Picornaviridae - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Infections Caused By Picornaviridae, H2 2014
  • Number of Products under Development for Infections Caused By Picornaviridae - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top